干血斑多重微球免疫法检测SARS-CoV-2血清流行率的开发与验证
本研究开发了针对SARS-CoV-2受体结合域(RBD)和核衣壳(N)的高通量多重微球免疫法(MMIA),灵敏度高于ELISA(98%对87%)。在264名科罗拉多急救人员中,用血清和干血斑(DBS)洗脱液验证MMIA,2020年7-8月血清阳性率为4%(11/264)。血清与DBS检测抗RBD和抗N抗体高度相关(R=0.83,P<0.0001;R=0.87,P<0.0001),MMIA用DBS可准确预测中和抗体(R=0.76,P=0.037)。3个月后复测,抗RBD IgG下降较抗N IgG慢,几何平均荧光强度中位变化分别为62%和79%(P<0.01)。
要点
- MMIA检测SARS-CoV-2抗体灵敏度高于ELISA(98%对87%)。
- 干血斑与血清检测抗RBD和抗N抗体高度相关。
- MMIA用干血斑可准确预测中和抗体。
核心结论
- MMIA使用干血斑可用于快速、可负担的SARS-CoV-2血清监测。
研究设计与样本
- 开发高通量SARS-CoV-2多重微球免疫法(MMIA),并在264名科罗拉多急救人员中用血清和干血斑洗脱液验证,与ELISA比较并评估中和抗体。
主要发现
- MMIA灵敏度为98%,ELISA为87%。
- 2020年7-8月264名急救人员中4%(11/264)血清阳性。
- 血清与DBS检测抗RBD和抗N抗体高度相关(R=0.83,P<0.0001;R=0.87,P<0.0001)。
- MMIA用DBS准确预测SARS-CoV-2中和抗体(R=0.76,P=0.037)。
- 3个月后复测,抗RBD IgG下降较抗N IgG慢,几何平均荧光强度中位变化分别为62%和79%(P<0.01)。
关键数值与推荐
- MMIA灵敏度98%对ELISA 87%。
- 血清与DBS抗RBD抗体R=0.83(P<0.0001),抗N抗体R=0.87(P<0.0001)。
- DBS预测中和抗体R=0.76(P=0.037)。
- 抗RBD与抗N IgG几何平均荧光强度中位变化62%对79%(P<0.01)。
临床怎么用
- 可采用干血斑结合MMIA进行大规模SARS-CoV-2血清流行率调查。
- 干血斑MMIA结果与血清高度相关,可替代血清用于抗体检测。
- MMIA可预测中和抗体,辅助评估免疫保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Serological testing of large representative populations for antibodies to SARS-CoV-2 is needed to estimate seroprevalence, transmission dynamics, and the duration of antibody responses from natural infection and vaccination. In this study, a high-throughput SARS-CoV-2 multiplex microsphere immunoassay (MMIA) was developed for the receptor binding domain (RBD) and nucleocapsid (N) that was more sensitive than enzyme-linked immunosorbent assay (ELISA) (98% versus 87%). The MMIA was then applied and validated in 264 first responders in Colorado using serum and dried blood spot (DBS) eluates, compared to ELISA, and evaluated for neutralizing antibodies. Four percent (11/264) of first responders were seropositive in July to August 2020. Serum and DBS were highly correlated for anti-RBD and anti-N antibodies (R = 0.83, P < 0.0001 and R = 0.87, P < 0.0001, respectively) by MMIA. The MMIA accurately predicted SARS-CoV-2 neutralizing antibodies using DBS (R = 0.76, P = 0.037). On repeat antibody testing 3 months later, anti-RBD IgG decreased less rapidly than anti-N IgG measured by MMIA, with a median change in geometric median fluorescence intensity of 62% versus 79% (P < 0.01) for anti-RBD and anti-N IgG, respectively. This novel MMIA using DBS could be scalable for rapid and affordable SARS-CoV-2 serosurveillance in the United States and globally.
引用
- Schultz JS, McCarthy MK, Rester C, et al. Development and Validation of a Multiplex Microsphere Immunoassay Using Dried Blood Spots for SARS-CoV-2 Seroprevalence: Application in First Responders in Colorado, USA. J Clin Microbiol. 2021. PMID: 33795412. doi:10.1128/JCM.00290-21
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。